quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:05:50·24d
SECFiling
Scienture Holdings Inc. logo

SEC Form 10-K filed by Scienture Holdings Inc.

SCNX· Scienture Holdings Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • SCNX
    Scienture Holdings Inc.
    Health Care

Related

  • PR8d
    Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
  • PR17d
    Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
  • PR24d
    SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
  • INSIDER42d
    President & Co-CEO Narasimhan Mani converted options into 1,357,538 shares, disposed of 20,000 shares and was granted 1,550,000 shares (SEC Form 4)
  • INSIDER42d
    Co-CEO & Chairman Shankar Hariharan converted options into 2,273,296 shares, disposed of 30,000 shares and was granted 1,550,000 shares, increasing direct ownership by 4,198% to 3,518,679 units (SEC Form 4)
  • PR43d
    SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
  • PR79d
    SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
  • PR99d
    SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022